Coronavirus has brought on more interest in the company, IO house, that creates homes that can be installed anywhere in 90 minutes.
Coronavirus has brought on more interest in the company, IO house, that creates homes that can be installed anywhere in 90 minutes.
Several supermarkets have agreed to waive the business rates holiday despite heavily criticising the tax regime in the past.
The IHS Markit/CIPS services purchasing managers’ index showed a reading of 47.6 for November, marking the first decline since June.
The New York Times reported on Tuesday that Trump talked with his personal lawyer Rudy Giuliani about pardoning him as recently as last week, citing two people briefed on the matter. The Times also said Trump has asked advisers about the possibility of "preemptively" pardoning his three eldest children. In 2018, Trump even said he had the "absolute right" to pardon himself - a claim many constitutional law scholars dispute.
Two records are reached on Wednesday, amid fears the pace will not slow leading up to Christmas.
Boris Johnson is set to unveil plans for world-leading emissions UK cuts - but are they enough?
Your Social Security income could be 30% lower if you claim early, but you can make up for the lost income in other areas of your budget.
Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Global Embolization Coil Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The embolization coil market is poised to grow by $215.58 million during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on embolization coil market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of aneurysms and availability of favourable reimbursement coverage. The embolization coil market analysis includes application segment and geographic landscape. This study identifies technological advances as one of the prime reasons driving the embolization coil market growth during the next few years. Also, market expansion in emerging economies and implementation of organic and inorganic strategies by market players will lead to sizable demand in the market. This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The embolization coil market report covers the following areas: * Embolization coil market sizing * Embolization coil market forecast * Embolization coil market industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading embolization coil market vendors that include Balt USA LLC, Boston Scientific Corp., Cook Group Inc., Cardinal Health Inc., Johnson & Johnson, ab medica Deutschland GmbH & Co. KG, Medtronic Plc, Shape Memory Medical Inc., Sirtex Medical Pty Ltd., and Terumo Corp. Also, the embolization coil market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth. Key Topics Covered: 1\. Executive Summary * Market Overview2\. Market Landscape * Market ecosystem * Market characteristics * Value chain analysis3\. Market Sizing * Market definition * Market segment analysis * Market size 2019 * Market outlook: Forecast for 2019 - 20244\. Five Forces Analysis * Five force summary * Bargaining power of buyers * Bargaining power of suppliers * Threat of new entrants * Threat of substitutes * Threat of rivalry * Market condition5\. Market Segmentation by Application * Market segments * Comparison by Application * Neurology - Market size and forecast 2019-2024 * Oncology - Market size and forecast 2019-2024 * Peripheral Vascular disease - Market size and forecast 2019-2024 * Cardiology - Market size and forecast 2019-2024 * Others - Market size and forecast 2019-2024 * Market opportunity by Application6\. Market Segmentation by Deployment * Market segments * Comparison by Deployment * Detachable coil - Market size and forecast 2019-2024 * Pushable coil - Market size and forecast 2019-2024 * Market opportunity by Deployment7\. Customer Landscape 8\. Geographic Landscape * Geographic segmentation * Geographic comparison * North America - Market size and forecast 2019-2024 * Europe - Market size and forecast 2019-2024 * APAC - Market size and forecast 2019-2024 * South America - Market size and forecast 2019-2024 * MEA - Market size and forecast 2019-2024 * Key leading countries * Market opportunity by geography * Market drivers * Market challenges * Market trends9\. Vendor Landscape * Vendor landscape * Landscape disruption10\. Vendor Analysis * Vendors covered * Market positioning of vendors * Balt USA LLC * Boston Scientific Corp. * Cook Group Inc. * Cardinal Health Inc. * Johnson & Johnson * ab medica Deutschland GmbH & Co. KG * Medtronic Plc * Shape Memory Medical Inc. * Sirtex Medical Pty Ltd. * Terumo Corp.11\. Appendix * Scope of the report * Currency conversion rates for US$ * Research methodology * List of abbreviationsFor more information about this report visit https://www.researchandmarkets.com/r/4w9gjtResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Biden is expected to announce his choice to head the Department of Health and Human Services next week. DEFENSE PRESSURE: Biden is facing escalating pressure from competing factions within his own party as he finalizes his choice for secretary of defense.
Julian Tello's music gigs started getting cancelled in March. Now he's faring better than most of his peers - here's how.
Tesco, Morrisons, Sainsbury’s and Aldi have pledged to return £1.4 billion back to the state.
TORONTO — Maple Leaf Sports and Entertainment's giant kitchen is open again.MLSE and its partners, who combined to donate 500,000 meals to front-line workers and community agencies from April to June, are reintroducing the 'Bringing Toronto Back to its Feet" program.Starting this week, the goal is to distribute more than 130,000 meals in early December.Scotiabank Arena will again be used to assemble the meals, which can be stored and frozen. They will later be distributed to community agencies and families who are struggling. MLSE’s chefs and food and beverage staff, along with other company employees, will prepare the meals for distribution.MLSE chairman Larry Tanenbaum. calls this holiday season "one of the most challenging that we have known."“This program will play a small part in helping our neighbours enjoy their holiday season as we all look forward to a better year ahead in 2021,” he said in a statement.Solidarity Kitchens, created by La Tablee des Chefs and financially supported by the Agriculture and Agri-Food Canada emergency fund, has given grants to Canadian initiatives, including Bringing Toronto Back To Its Feet, with a goal of creating two million meals for those in need across the country.“As the pandemic continues to impact our communities and we approach the holiday season, there is no better time to come together to support those in need and we want to thank everyone who is helping to make a return of this important program possible, including MLSE’s ownership group and our founding corporate partners,” said MLSE president and CEO Michael Friisdahl.Second Harvest, the largest food rescue organization in Canada, along with a network of local suppliers and sponsors, are supplying fresh ingredients daily to the MLSE team.The chefs will then turn those supplies, along with other food purchased or donated to the program, into ready-to-heat meals meeting a variety of dietary needs. The meals will delivered five days a week.The meal donation program sees MLSE chefs spread out in Scotiabank Arena kitchens, physically distanced as they cook using giant 120-litre pots. Routes have been set up in the arena to control the flow of traffic and food, from the loading dock to kitchen to meal assembly line.The chefs stay in the kitchen. Others take the food from the kitchen to an open space in the arena to be assembled and packaged into meals. Earlier this year, that was the arena floor. This time, the meals are being put together in the concourse.Once cooked, the food is cooled in fridges, then assembled quickly and covered, wrapped and refrigerated again to await distribution and reheating.At its peak, the MLSE-led program produced 13,000 meals per day, providing meals to more than 75 community agencies and front-line health-care workers and their families at 25 hospitals and health-care facilities in the Greater Toronto Area.“We have heard first-hand about the incredible impact these prepared meals have on the lives of people struggling with hunger and limited access to food programs,” said Lori Nikkel, CEO of Second Harvest. MLSE is working with food hygiene experts and Toronto Public Health to ensure the safety of the meals and of the people preparing them.MLSE owns the Toronto Maple Leafs, Raptors, Argonauts, Marlies and Toronto FC.\---Follow @NeilMDavidson on Twitter This report by The Canadian Press was first published Dec. 3, 2020Neil Davidson, The Canadian Press
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 December 2020) Immunocore (or the “Company”), a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that it will present new clinical results on tebentafusp (IMCgp100) at the European Society of Medical Oncology Immuno-Oncology (ESMO IO) Virtual Congress on the 12th December. These data represent the primary clinical results from a Phase 2 study of tebentafusp in previously treated, metastatic uveal melanoma (mUM) patients.The Phase 2 study investigated the overall response rate (ORR), with secondary objectives being overall survival (OS) and safety in 127 patients who had enrolled after progressing on one or more prior therapies. During the session, Dr. Joseph Sacco, Consultant in Medical Oncology, Clatterbridge Cancer Centre, will present the clinical results from the trial.“In this phase 2 study of previously treated metastatic uveal melanoma, we observed a promising survival that replicates the overall survival benefit we recently reported in our randomized phase 3 study in previously untreated patients,” said David Berman, Head of Research and Development at Immunocore. “TCR bispecifics represent a new frontier in IO which will require matching science to clinical observation. Because the proposed mechanism of action includes redirecting T cells into a solid tumor, the survival benefit in patients treated with tebentafusp showed the potential to extend beyond RECIST-defined response rate to also include immune-related responses.”In this Phase 2 study, the overall RECIST-defined response rate (ORR) was 5%, with 45% of patients achieving stable disease. Among patients with evaluable tumours, 44% had reduction in the sum of target lesions, including demonstration of immune-related responses. Median overall survival (OS) was 16.8 months, with a 12-month OS rate of 62%. The historical 12-month OS rate in previously treated patients is approximately 40%.Patients who developed a rash, a proposed on-target adverse event (AE), within 7 days of starting tebentafusp had a 12-month OS rate of 77% compared to approximately 40% of those who did not develop a rash. Patients with any reduction in the sum of target lesions, including those with immune-related responses, had a 12-month OS rate of 86%.Treatment-related AEs were consistent with the proposed mechanism of action, and were generally manageable and decreased in severity after the first three doses; only 3.7% of patients discontinued treatment due to a related AE and there were no fatal treatment-related AEs.\- Ends -About Immunocore Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, U.K., with offices in Conshohocken, Pennsylvania and Rockville, Maryland in the United States. For more information, please visit www.immunocore.com.About ImmTAC® MoleculesImmunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognise and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumours, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumours. About TebentafuspTebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Fast Track Designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).About Uveal MelanomaUveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment., Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).,, Up to 50% of people with uveal melanoma will eventually develop metastatic disease.1,2 When the cancer spreads beyond the eye, only approximately half of patients will survive for one year.For more information, please contact:Immunocore Debra Nielsen, Head of Communications T: +1 (610) 368-8602 E: firstname.lastname@example.org Follow on Twitter: @ImmunocoreConsilium Strategic Communications (corporate and financial) Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji T: +44 (0)203 709 5700 E: Immunocore@consilium-comms.com Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 2019;11(7):971. Carvajal, RD, Schwartz, GK, Tezel, T, et al., 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 101(1), 38-44. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):1230-1244. About ocular melanoma. Ocular Melanoma Foundation website. www.ocularmelanoma.org/about-om.htm. Accessed September 2019. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019
The TV star already has a daughter named Nelly.
IBM says organisations involved in storing and moving coronavirus vaccines at chilled temperatures.
Falling review – Viggo Mortensen casts a clear eye on dementia. In the Lord of the Rings star’s powerful debut as a director, Lance Henriksen plays a homophobic father compelled to move in with his gay son
When technical problems marred the ballyhooed launch of the Affordable Care Act's website, President Barack Obama turned to Jeff Zients, an economic adviser touted for his managerial skills, to repair Obama's signature policy rollout. Seven years later, Obama's vice president, President-elect Joe Biden, is considering tapping Zients to tackle a far more daunting problem as the incoming administration's coronavirus "czar," according to a Biden ally briefed on his thinking. The prominent position would be similar to the role that Ron Klain, Biden's soon-to-be chief of staff, played for the Obama administration during the Ebola crisis in 2014.
Continuing to push the envelope with advanced ultrasound depth and detail plus ultimate comfort features for enhanced sonographer workflow, Canon Medical Systems USA, Inc. will showcase its premium Aplio i-series ultrasound platform with new design features at this year’s virtual Radiological Society of North America (RSNA) annual meeting.
From Hollywood to New York and everywhere in between, see what your favorite stars are up to
Piedmont Lithium Limited ("Piedmont" or "Company") is pleased to announce that it has received from the North Carolina Department of Environmental Quality ("NCDEQ") Division of Air Quality ("DAQ") the air permit ("Permit") to construct and operate the Company’s planned 22,700 t/y lithium hydroxide chemical plant located in Kings Mountain, North Carolina.
OpenWorks introduces TotalWorks with Continuous Care, providing up to 90 days of bacteria protection